Form 4: Acurx Pharmaceuticals Director Receives Stock Options

Director Jack H. Dean was granted 2,150 stock options as part of the Acurx Pharmaceuticals director compensation policy.

Summary

• Director Jack H. Dean received a grant of 2,150 stock options on April 20, 2026.
• The options have an exercise price of $2.36 per share.
• The options are scheduled to vest on April 20, 2027, and expire on April 20, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on company operations or financial health.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• Minor dilution of existing shareholders upon the eventual exercise of these options.

Risks

• Market price volatility could impact the future value of the granted options.

Future Outlook

The filing does not provide forward-looking financial guidance, as it is a standard disclosure of director compensation.

Industry Context

StockSavvy.ai notes that equity grants for board members are standard practice in the biotechnology sector to incentivize oversight and long-term strategic alignment without immediate cash outlays.

Comparison to Industry Standards

• The grant follows standard corporate governance practices for small-cap biotech firms.
• The vesting period of one year is consistent with typical director compensation policies.

Corporate Governance

Stakeholder Impact

• Minimal impact on shareholders due to the small size of the grant.

Next Steps

• Vesting of options on April 20, 2027.

Key Dates

Keywords

Acurx Pharmaceuticals, ACXP, Director Compensation, Stock Options, Insider Transaction, Form 4